Arbutus Biopharma (NASDAQ:ABUS) Price Target Raised to $5.00 at JMP Securities

Arbutus Biopharma (NASDAQ:ABUS) had its price objective lifted by JMP Securities to $5.00 in a report released on Wednesday morning, Stock Target Advisor reports. They currently have a buy rating on the biopharmaceutical company’s stock.

A number of other analysts also recently issued reports on ABUS. StockNews.com raised shares of Arbutus Biopharma from a “sell” rating to a “hold” rating in a research report on Saturday, August 10th. Jefferies Financial Group increased their price objective on shares of Arbutus Biopharma from $5.00 to $7.00 and gave the stock a “buy” rating in a research report on Thursday, September 5th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $5.38.

Arbutus Biopharma Price Performance

NASDAQ ABUS opened at $3.92 on Wednesday. The company has a 50-day moving average of $4.04 and a 200-day moving average of $3.57. Arbutus Biopharma has a 12 month low of $1.70 and a 12 month high of $4.72. The company has a market cap of $740.02 million, a P/E ratio of -8.71 and a beta of 1.92.

Institutional Trading of Arbutus Biopharma

Large investors have recently bought and sold shares of the company. The Manufacturers Life Insurance Company boosted its stake in shares of Arbutus Biopharma by 7.9% in the second quarter. The Manufacturers Life Insurance Company now owns 57,323 shares of the biopharmaceutical company’s stock valued at $177,000 after purchasing an additional 4,191 shares during the period. Premier Path Wealth Partners LLC increased its position in shares of Arbutus Biopharma by 18.0% during the second quarter. Premier Path Wealth Partners LLC now owns 36,000 shares of the biopharmaceutical company’s stock worth $111,000 after acquiring an additional 5,500 shares during the last quarter. Creative Planning lifted its stake in shares of Arbutus Biopharma by 13.8% in the third quarter. Creative Planning now owns 49,500 shares of the biopharmaceutical company’s stock worth $191,000 after acquiring an additional 5,989 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in Arbutus Biopharma by 22.4% in the first quarter. Price T Rowe Associates Inc. MD now owns 36,388 shares of the biopharmaceutical company’s stock valued at $94,000 after purchasing an additional 6,649 shares during the last quarter. Finally, Verus Capital Partners LLC increased its stake in shares of Arbutus Biopharma by 30.5% in the first quarter. Verus Capital Partners LLC now owns 41,935 shares of the biopharmaceutical company’s stock worth $108,000 after buying an additional 9,800 shares during the last quarter. Institutional investors and hedge funds own 43.79% of the company’s stock.

About Arbutus Biopharma

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.